Last reviewed · How we verify
API 31510
At a glance
| Generic name | API 31510 |
|---|---|
| Sponsor | BPGbio |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) (PHASE2)
- BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients (PHASE2)
- Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma (PHASE1, PHASE2)
- BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors (PHASE1)
- Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia (EARLY_PHASE1)
- BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab (PHASE1)
- Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa (PHASE1)
- An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- API 31510 CI brief — competitive landscape report
- API 31510 updates RSS · CI watch RSS
- BPGbio portfolio CI